

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Raily Aesthetic Medicine International Holdings Limited**

**瑞麗醫美國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2135)**

### **SUPPLEMENTAL ANNOUNCEMENT TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2020**

References are made to the section headed “Future Plans and Use of Proceeds” of the prospectus of Raily Aesthetic Medicine International Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 15 December 2020 (the “**Prospectus**”) and the sections headed “Management Discussion and Analysis — Use of Proceeds” and “Directors’ Report — Use of Net Proceeds from the Global Offering” in the annual report of the Group for the year ended 31 December 2020 (the “**2020 Annual Report**”) published on 16 April 2021. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Prospectus and the 2020 Annual Report.

This announcement is made to provide supplemental information to the 2020 Annual Report and an update to the use of proceeds from the listing of the Company’s securities on the Stock Exchange of Hong Kong Limited on 28 December 2020 (the “**Listing**”).

The net proceeds of the Listing (including exercise of the Over-allotment Option and after deducting the underwriting fees, commissions and all related expenses in connection to the Listing) amounted to approximately HK\$81.7 million (the “**Net Proceeds**”). From the date of Listing to 31 December 2020, the Group has not utilised any Net Proceeds. As of 31 December 2020, the unutilised amount is approximately HK\$81.7 million.

In addition to the information in the sections headed “Management Discussion and Analysis — Use of Proceeds” and “Directors’ Report — Use of Net Proceeds from the Global Offering” in the 2020 Annual Report, the Board would like to provide additional information pursuant to paragraphs 11(8) of Appendix 16 to the Rules Governing the Listing of Securities on the Stock Exchange in relation to the use of Net Proceeds as follows:

Purpose	Percentage to total amount	Planned use of net proceeds <i>HK\$’ million</i>	Actual use of proceeds up to 31 December 2020 <i>HK\$’ million</i>	Unutilised amount as of 31 December 2020 <i>HK\$’ million</i>	Expected timeline of full utilisation of the remaining proceeds
Expanding our aesthetic medical institutions network	71.0%	58.0	—	58.0	31 December 2023
— Renovation and expansion of existing aesthetic medical institutions	28.0%	22.9	—	22.9	31 December 2023
— Organic growth	28.0%	22.9	—	22.9	31 December 2023
— Strategic acquisitions	15.0%	12.2	—	12.2	31 December 2023
Acquire new aesthetic medical service equipment and treatment consumables to extend the spectrum of our treatment services offered in our current aesthetic medical institutions	11.0%	9.0	—	9.0	31 December 2022
Actively promote our brand	8.0%	6.5	—	6.5	31 December 2023
General working capital	10.0%	8.2	—	8.2	31 December 2023
<b>Total</b>	<b>100.0%</b>	<b>81.7</b>	<b>—</b>	<b>81.7</b>	

The Group intends to apply the remaining proceeds as shown above and in accordance with the purposes set out in the section headed “Future Plans and Use of Proceeds” in the Prospectus. The expected timeline for utilising the remaining proceeds is based on the best estimation of the future market conditions made by the Group. It will be subject to change based on the current and future development of market conditions.

The above additional information does not affect other information contained in the 2020 Annual Report and save as disclosed above, all other information in the 2020 Annual Report remains unchanged.

By order of the Board  
**Raily Aesthetic Medicine International Holdings Limited**  
**Mr. Fu Haishu**  
*Chairman*

Hong Kong, 13 July 2021

*As of the date of this announcement, the Board comprises Mr. Fu Haishu, Mr. Yu Kai and Mr. Song Jianliang as executive Directors; Mr. Xie Lijun and Ms. Fan Qirui as non-executive Directors; and Mr. Cao Dequan, Ms. Yang Xiaofen and Mr. Liu Teng as independent non-executive Directors.*